Every 424B that Sonoma Pharmaceuticals, Inc. (SNOA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SNOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNOA filings page.
Sonoma Pharmaceuticals amends its prospectus supplement to increase its at-the-market offering capacity to $3,641,703. The company will continue to sell common stock through Ladenburg Thalmann under an ATM agreement; prior sales under the prospectus supplement totaled $574,633 from 173,073 shares.
The supplement replaces the previously stated maximum aggregate offering price of $2,070,463 with $3,641,703. As of June 18, 2026, the public float was reported at $12,649,011, calculated on 4,785,801 shares outstanding and a closing price of $2.65 per share on April 20, 2026. The filing notes the company may not sell more than one-third of its public float in any 12-month period under General Instruction I.B.6 of Form S-3.
Sonoma Pharmaceuticals, Inc. is offering up to 2,962,962 units, each consisting of one share of common stock (or a Pre-Funded Warrant in lieu thereof) and one common warrant, at a public offering price of $1.35 per unit, in a firm commitment underwriting for gross proceeds of approximately $4.0 million. Each common warrant is exercisable immediately at $1.35 and expires five years after issuance. The offering includes Pre-Funded Warrants to permit purchasers to avoid exceeding 4.99% (or, at election, 9.99%) beneficial ownership limits; Pre-Funded Warrants have an exercise price of $0.0001 and no expiration date. The underwriters have a 45-day option to purchase up to 444,444 additional shares/warrants. Net proceeds are intended for working capital and general corporate purposes. The company’s common stock trades on Nasdaq under the symbol SNOA.
Sonoma Pharmaceuticals, Inc. is offering up to 492,967 shares of common stock in an at-the-market type offering at an example price of $4.20 per share. Prior to the offering there were 1,649,765 shares outstanding and the company states that up to 2,142,732 shares could be outstanding after the offering depending on sales price and authorization limits. Net proceeds are intended for working capital and general corporate purposes. The prospectus supplement discloses 105,500 RSUs outstanding that may dilute shareholders and shows a pro forma net tangible book value per share (adjusted for option exercises after June 30, 2025) of $2.47 with an increase attributable to the offering of $0.34 per share. The filing refers investors to the "Risk Factors" section and to incorporated reports including annual and quarterly reports and current reports filed in 2023 and 2025 for additional information.